Page last updated: 2024-08-05 11:20:48
primary carboxamide
A carboxamide resulting from the formal condensation of a carboxylic acid with ammonia; formula RC(=O)NH2.
ChEBI ID: 140324
Members (24)
| Member | Definition | Role |
|---|---|---|
| 1,2,4-triazole-3-carboxamide | A member of the class of triazoles that is 1H-1,2,4-triazole substituted by an aminocarbonyl group at position 3. It is the major catabolite and aglycon of ribavirin. | 1,2,4-triazole-3-carboxamide |
| 2-cyano-2-cyclohexylideneacetamide | 2-cyano-2-cyclohexylideneacetamide | |
| acrylamide | A member of the class of acrylamides that results from the formal condensation of acrylic acid with ammonia. | acrylamide |
| caproamide | A fatty amide of hexanoic acid. | hexanamide |
| cefsulodin | A pyridinium-substituted semi-synthetic, broad-spectrum, cephalosporin antibiotic. | cefsulodin |
| CHIC-35 | An organic heterotricyclic compound resulting from the formal fusion of the 2-3 bond of 5-chloroindole with the 2-3 bond of cycloheptanecarboxamide (the S enantiomer). It is a potent, cell-permeable, metabolically stable and selective inhibitor of the deacetylase SIRT1. | CHIC-35 |
| favipiravir | A member of the class of pyrazines that is pyrazine substituted by aminocarbonyl, hydroxy and fluoro groups at positions 2, 3 and 6, respectively. It is an anti-viral agent that inhibits RNA-dependent RNA polymerase of several RNA viruses and is approved for the treatment of influenza in Japan. | favipiravir |
| furylfuramide | A member of the class of acrylamides that is acrylamide which is substituted at positions 2 and 3 by 2-furyl and 5-nitro-2-furyl groups, respectively (the trans isomer). Formerly used as a food preservative, it was withdrawn from the market following suspicions of carcenogenicity. | (Z)-2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide |
| gilteritinib | A member of the class of pyrazines that is pyrazine-2-carboxamide which is substituted by {3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}nitrilo, (oxan-4-yl)nitrilo and ethyl groups at positions 3,5 and 6, respectively. It is a potent inhibitor of FLT3 and AXL tyrosine kinase receptors (IC50 = 0.29 nM and 0.73 nM, respectively). Approved by the FDA for the treatment of acute myeloid leukemia in patients who have a FLT3 gene mutation. | gilteritinib |
| labetalol | A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5. | 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide |
| methacrylamide | methacrylamide | |
| N-(3-carbamoyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-2-pyrazinecarboxamide | N-(3-carbamoyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-2-pyrazinecarboxamide | |
| n-acetyltryptophanamide | (2S)-2-acetamido-3-(1H-indol-3-yl)propanamide | |
| naphthaleneacetamide | A member of the class of naphthalenes that is naphthalene which is substituted by a 2-amino-2-oxoethyl group at position 1. It is a synthetic auxin that is widely used in agriculture to promote the growth of numerous fruits, for root cuttings and as a fruit thinning agent. | 1-naphthaleneacetamide |
| niraparib | A member of the class of indazoles that is 2H-indazole substituted by 4-(piperidin-3-yl)phenyl and aminocarbonyl groups at positions 2 and 7, respectively. It is a potent PARP1 inhibitor with IC50 of 3.2 nM. | 2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide |
| pelabresib | An organic heterotricyclic compound that is 4H-[1,2]oxazolo[5,4-d][2]benzazepine substituted by methyl, 2-amino-2-oxoethyl, and 4-chlorophenyl groups at positions 1, 4S and 6, respectively. It is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins and exhibits antineoplastic activity. | pelabresib |
| ribavirin | A 1-ribosyltriazole that is the 1-ribofuranosyl derivative of 1,2,4-triazole-3-carboxamide. A synthetic guanosine analogue, it is an inhibitor of HCV polymerase and possesses a broad spectrum of activity against DNA and RNA viruses. | ribavirin |
| ribavirin 5'-diphosphate | A 1-ribosyltriazole that is ribavirin in which the hydroxy group at the 5'-position is replaced by a phosphonooxy group. It is the active metabolite of the antiviral agent ribavirin. | ribavirin 5'-monophosphate |
| ribavirin 5'-diphosphate | A 1-ribosyltriazole that is ribavirin in which the hydroxy group at the 5'-position is replaced by a diphosphate group. It is the metabolite of the antiviral agent ribavirin. | ribavirin 5'-diphosphate |
| ribavirin 5'-triphosphate | A 1-ribosyltriazole that is ribavirin in which the hydroxy group at the 5'-position is replaced by a triphosphate group. It is the active metabolite of the antiviral agent ribavirin. | ribavirin 5'-triphosphate |
| tyrphostin ag825 | An organic sulfide that consists of 1,3-benzothiazole-2-thiol in which the hydrogen attached to the sulfur atom is replaced by a 5-[(1E)-3-amino-2-cyano-3-oxoprop-1-en-1-yl]-2-hydroxy-3-methoxybenzyl group. It acts as an epidermal growth factor receptor antagonist. | tyrphostin AG 825 |
| varespladib | A member of the class of indoles that is 1H-indole substituted by benzyl, ethyl, oxamoyl, and carboxymethoxy groups at positions 1, 2, 3, and 4, respectively. It is an oral secretory phospholipase A2 inhibitor and exhibits anti-inflammatory effects. | varespladib |
| varespladib methyl | A methyl ester resulting from the formal condensation of the carboxy group of varespladib with methanol. It is a potential therapy for the treatment of snakebite envenomings in which toxicity depends on the action of PLA2s. | varespladib methyl |
| vindesine | vindesine |
Research
Studies (19,366)
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2,629 (13.58) | 18.7374 |
| 1990's | 2,020 (10.43) | 18.2507 |
| 2000's | 5,564 (28.73) | 29.6817 |
| 2010's | 7,232 (37.34) | 24.3611 |
| 2020's | 1,921 (9.92) | 2.80 |
Study Types
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 2,850 (13.68%) | 5.53% |
| Reviews | 2,680 (12.86%) | 6.00% |
| Case Studies | 1,767 (8.48%) | 4.05% |
| Observational | 222 (1.07%) | 0.25% |
| Other | 13,315 (63.91%) | 84.16% |